 |
<이미지를 클릭하시면 크게 보실 수 있습니다> |
SEOUL -- Clinical trials are underway in South Korea to test the safety and efficacy of ten treatment and two vaccine candidates. South Korea's health regulatory agency said that five more are under review to see if they are suitable for a national campaign to contain a new coronavirus pandemic.
Candidates for remedies listed by the Ministry of Food and Drug Safety included camostat mesilate, ciclesonide, clevudine, nafamostat mesilate, ifenprodil, EC-18 (synthetic monoacetyldiglyceride), pyronaridine phosphate/Artesunate, and baricitinib sold under the brand name of Olumiant.
The two vaccines are GX-19, a DNA vaccine material developed by Genexine, a clinical-stage biotechnology company in South Korea, and INO-4800 developed by Inovio Pharmaceuticals, an American biotechnology company.
Genexine is involved in joint vaccine research in Indonesia, Thailand and Turkey. South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year.
Lim Chang-won Reporter cwlim34@ajunews.com
Lim Chang-won cwlim34@ajunews.com
- Copyright ⓒ [아주경제 ajunews.com] 무단전재 배포금지 -
이 기사의 카테고리는 언론사의 분류를 따릅니다.
기사가 속한 카테고리는 언론사가 분류합니다.
언론사는 한 기사를 두 개 이상의 카테고리로 분류할 수 있습니다.
언론사는 한 기사를 두 개 이상의 카테고리로 분류할 수 있습니다.
